Bailard’s Standard BioTools LAB Stock Holding History

Bailard’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-12,800	Closed	-$45K	–	524
2019 Q4	$45K	Hold	12,800	–	–	﹤0.01%	534
2019 Q3	$59K	Buy	+12,800	New	+$101K	﹤0.01%	525

Other funds holding LAB

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

EIP

Easterly Investment Partners Beverly, Massachusetts $1.31B AUM 18.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bailard's LAB Position: Q1 2020 in Review

Bailard sold out of Standard BioTools (LAB) in Q1 2020, closing a stake of 12,800 shares — an estimated $45K sold.

Bailard first reported a position in LAB in Q3 2019 and held it in 2 quarters. The position peaked at $59K in Q3 2019. 103 funds tracked by Wall St. Rank hold LAB as of Q1 2020.

Bailard reported no remaining Standard BioTools position as of Q1 2020 after selling out during the quarter.
Bailard sold 12,800 Standard BioTools shares in Q1 2020, an estimated $45K.
Bailard first reported a position in Standard BioTools in Q3 2019 and held it in 2 quarters.
Bailard's Standard BioTools position peaked at $59K in Q3 2019.
103 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2020.

Based on Bailard's 13F filing for Q1 2020, filed 16 Apr 2020.